Life Science Nation Newsletter  | December 14,  2017  |  Issue 244

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Dec. 7  - Dec. 13)
Seeking Opportunities in Biotech and Healthcare
Focused Exclusively in Oncology Therapies Globally
Makes Strategic Medtech Investments in the Cardiovascular and Neurostimulation Space
Invests in Digital Health Companies with USA Focus
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation's Redefining Early Stage Investments (RESI) conference is a partnering event that requires high touch on both the buy side (investors and pharma) and sell side (startup) constituents.To do partnering correctly takes a high human resource allocation; it is expensive to fund, and requires deep curation of a clientele database for each conference iteration. LSN has discovered that our database curation begets savvy list management, which in turn allows us to target constituents and provide them with customer support and training to use the partnering system efficiently. In today's life science domain, conferences still lead as a place to make new business connections in addition to accessing the latest information on the advances in drugs, devices, diagnostics, and healthcare IT.

Informational-based life science conferences have worked for decades to successfully "break the profitability code". Breaking the code means finding the precise point between internal resource output and maximum revenue gain, and balancing on it. The irony here is that if the conferences wish to be part of the industry's new trend of relationship-based conferences with a strong partnering component...

By Claire Jeong, Research Analyst, LSN

With RESI San Francisco less than a month away, we are proud to announce the Medical Device investors panel, where 5 seasoned experts in medical device investments will discuss how they seek to work with early-stage medical technology entrepreneurs.

The fundraising process and path to commercialization for medical device products continue to be a rigorous challenge for many budding companies. Especially with the exponential growth of the IoT/IoMT market, a growing number of entrepreneurs are focusing on the development of connected, "smarter" devices that incorporate a software or data component. Although often overshadowed by the biopharmaceutical industry in terms of degree of need or financial returns, the medical device sector is a very much needed area in the improvement of healthcare. If you are a medical device entrepreneur and heading to San Francisco for JPM week, you do not want to miss out on our RESI Medical Devices panel! Our panelists are:
  • Renee Ryan, Vice President, JJDC, Johnson & Johnson Innovation (JLABS)
  • Yao Li Ho, Director of Business Development, LYFE Capital
  • Zishan "Z" Haroon, Chairman & General Partner, Julz Co LLC
  • Sam Ifergan, President & CEO, iGan Partners
  • Randy Scott, Partner, HealthQuest Capital
By Lucy Parkinson, Director of Research, LSN

Nonprofits and foundations have long played a part in funding basic research into disease biology. However, it takes more financing and development resources for this valuable work to create new products that make an impact on patients. This has caused a trend in the philanthropic space toward investing in early stage life science ventures that have the power to transform treatment in a space of unmet need or to significantly improve health outcomes. Simultaneously, some financially-minded investors have seen the possibility of investing more meaningfully, and have chosen to put their wealth to work in venture funds that look for a 'double bottom line' - a good return on capital plus a positive result for the world.

At RESI San Francisco, this investment trend is showcased at the Venture Philanthropy and Impact Investment panel. This panel features both philanthropic organizations and for-profit investment funds, with focuses ranging from a rare disease with no cure to the broad goal of improving healthcare. We're looking forward to what should be a wide-ranging discussion on how these investors find the right startup investing opportunities to fulfil their respective missions.

Moderated by John Reher, Managing Director - Brain Trust Accelerator Fund, the panelists are:
  • Debra Miller, Founder - CureDuchenne Ventures
  • Ken LaMontagne, VP, Research - Leukemia & Lymphoma Society (LLS)
  • William Werkmeister, Partner, ICIF Fund - National Foundation for Cancer Research
  • Cynthia Ringo, Managing Partner - DBL Partners

Created & Produced by

QuickFire Challenge
I n honor of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award up to four new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ NYC community for one year.

This competition will award the person or team(s) who submits the best idea, technology, or solution in the following areas:
  • Consumer healthcare
  • Health technologies
  • Medical devices
  • Therapeutics